Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets

Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer

Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.

Granules India inaugurated water tank at Bonthapally village

The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.

NATCO launches Chlorantraniliprole combination agro products in India

Both products are broad-spectrum, foliar insecticides used across wide range of crops

Lupin receives approval from USFDA for Darunavir Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.

Casper Pharma receives EIR from USFDA for its PAI

The inspection concluded with no observation (FDA-483) issued.

Zydus receives USFDA tentative approval for Amantadine Extended-Release capsules

Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data

Matt Sause elevated as new CEO of Roche Diagnostics

Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.

Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency

AGC begins study to expand its Bio-CDMO capability in Japan